糖尿病患者PCI中Abluminus DES+对比XIENCE依维莫司支架的随机试验
ABILITY Diabetes Global为多中心、前瞻性、开放标签、随机对照试验,纳入3032例接受PCI的糖尿病患者,比较Abluminus DES+西罗莫司洗脱支架与XIENCE依维莫司洗脱支架。12个月符合方案分析显示,Abluminus DES+在缺血驱动的靶病变血运重建和靶病变失败两个共同主要终点上均未达到非劣效。两组12至24个月事件率相似。
要点
- 糖尿病患者PCI后Abluminus DES+的12个月靶病变失败率高于XIENCE EES。
- 缺血驱动的靶病变血运重建在Abluminus DES+组更常见。
- 两组心血管死亡和全因死亡未见显著差异。
核心结论
- 在糖尿病患者PCI中,Abluminus DES+西罗莫司洗脱支架对比XIENCE依维莫司洗脱支架未达到非劣效,12个月缺血驱动的靶病变血运重建和靶病变失败率更高。
研究设计与样本
- ABILITY Diabetes Global为多中心、前瞻性、开放标签、随机对照试验,在16个国家74个中心开展。
- 纳入3032例≥18岁的1型或2型糖尿病成人患者,因慢性冠脉综合征或非ST段抬高型急性冠脉综合征接受至少一处原位冠脉病变PCI。
- 患者按1:1随机分配至Abluminus DES+西罗莫司洗脱支架组(n=1514)或XIENCE依维莫司洗脱支架组(n=1518)。
主要发现
- 24个月意向性治疗分析结果与12个月一致,12至24个月界标分析两组无显著差异。
关键数值与推荐
- Abluminus DES+组推荐球囊扩张时间至少45秒以促进药物转移;所有患者按指南和当地实践接受双联抗血小板治疗。
临床怎么用
- 在糖尿病患者PCI中,XIENCE依维莫司洗脱支架在12个月靶病变相关结局上优于Abluminus DES+西罗莫司洗脱支架。
- Abluminus DES+用于糖尿病患者PCI时需关注缺血驱动的靶病变血运重建和靶血管心肌梗死风险。
- 支架选择和辅助药物治疗仍需持续优化以降低糖尿病患者残余缺血风险。
局限性
- 研究为开放标签设计,术者知晓分组。
- 非劣效性假设未达成,结果提示Abluminus DES+在主要终点上劣于XIENCE EES。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with coronary artery disease, diabetes increases the risk of restenosis and adverse cardiovascular events after percutaneous coronary intervention (PCI). The Abluminus DES+ is a thin-strut cobalt-chromium sirolimus-eluting stent (SES) with abluminal and balloon-surface coating intended to enhance drug delivery to the vessel wall. We aimed to compare the efficacy and safety of the Abluminus DES+ SES versus the XIENCE durable-polymer everolimus-eluting stent (EES) in patients with diabetes undergoing PCI. METHODS: ABILITY Diabetes Global was a multicentre, prospective, open-label, randomised controlled trial conducted at 74 sites in 16 countries. Adults (aged ≥18 years) with type 1 or type 2 diabetes undergoing PCI for at least one de novo coronary lesion due to chronic coronary syndrome or non-ST-elevation acute coronary syndrome were eligible. Patients were randomly assigned (1:1) to the Abluminus DES+ SES or the XIENCE EES. Randomisation was stratified by site using a secure web-based system with concealed allocation and randomly varying block sizes (4, 6, and 8). Operators were unmasked to allocation; staff performing clinical follow-up and the independent clinical events committee were masked. For the Abluminus DES+ SES, a balloon inflation time of at least 45 s was recommended to facilitate drug transfer; dual antiplatelet therapy was prescribed to all patients according to clinical guidelines and local practice. The primary hypothesis of the study was the non-inferiority of the Abluminus DES+ SES compared with the XIENCE EES for the two coprimary endpoints at 12 months (in the per-protocol population): ischaemia-driven target-lesion revascularisation (2·8% non-inferiority margin) and target-lesion failure (3·0% margin), defined as a composite of cardiovascular death, target-vessel myocardial infarction, or ischaemia-driven target-lesion revascularisation. Time-to-event analyses were conducted with Kaplan-Meier estimates and Cox proportional hazards models. This trial is registered with ClinicalTrials.gov (NCT04236609) and is complete. FINDINGS: Between June 12, 2020, and Sept 9, 2022, 3032 patients were randomly assigned to the Abluminus DES+ SES (n=1514) or XIENCE EES (n=1518). 2931 (96·7%) of 3032 patients completed follow-up to death or 24-month follow-up. Median age was 68·0 years (IQR 60-74). 879 (29·0%) of 3032 patients were female and 2153 (71·0%) were male. At 12 months, in the per-protocol analysis, the Abluminus DES+ SES did not meet the criteria for non-inferiority for ischaemia-driven target-lesion revascularisation compared with XIENCE EES (67 of 1421 patients [Kaplan-Meier estimate 4·8%, 95% CI 3·9-6·2] vs 30 of 1446 [2·1%, 95% CI 1·6-3·2]; absolute risk difference 2·7%, 95% CI 1·3-4·1; pnon-inferiority=0·44) and target lesion failure (137 [9·7%, 8·4-11·5] vs 89 [6·2%, 5·3-7·8]; 3·5%, 1·5-5·5; pnon-inferiority=0·68). For both endpoints, the lower bound of the 95% CI for the absolute risk difference excluded zero. Target-vessel myocardial infarction occurred more frequently in the Abluminus DES+ SES group (73 of 1421 patients [Kaplan-Meier estimate 5·2%, 95% CI 4·1-6·5] vs 44 of 1446 patients [3·1%, 2·4-4·3]) but there were no significant differences in cardiovascular death (41 of 1421 patients [2·9%, 2·1-3·9] vs 30 of 1446 patients [2·1%, 1·5-3·0]) and all-cause death (52 of 1421 patients [3·7%, 2·8-4·8] vs 48 of 1446 patients [3·3%, 2·5-4·4]). Results were consistent at 24 months in the intention-to-treat analysis, however no significant differences were observed between the two groups in landmark analyses between 12 and 24 months. INTERPRETATION: In patients with diabetes undergoing PCI, the Abluminus DES+ SES was not non-inferior to the XIENCE EES, resulting in higher rates of ischaemia-driven target-lesion revascularisation and target lesion failure at 12-month follow-up. Event rates between 12 and 24 months were similar between groups. These findings highlight the persistent challenge of optimising outcomes in patients with diabetes and underscore the need for continued innovation in stent design and adjunctive pharmacotherapy to reduce residual ischaemic risk in this population. FUNDING: Concept Medical.
引用
- Abizaid, Mehran, Oliva, et al. Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial. Lancet. 2026. PMID: 41520674. doi:10.1016/S0140-6736(25)02157-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。